Pablo Cagnoni is president and chief executive officer of Rubius Therapeutics. Over the course of Pablo’s career as an oncologist and pharmaceutical executive, he has been committed to advancing the development of breakthrough treatments for people with cancer and other diseases. He has played a key role in the development, approval and commercialization of more than 20 life-changing treatments, including Afinitor®, Kyprolis® and Tarceva®.
Before joining Rubius in 2018, Pablo served as President and Chief Executive Officer of Tizona Therapeutics, a privately held biotech company focused on developing next generation immunotherapies for the treatment of cancer. He joined Tizona as the company’s first employee and grew the organization to support the filing of its first Investigational New Drug application. In 2020, Gilead Sciences secured an exclusive option to acquire Tizona for up to $1.5 billion. Prior to Tizona, he served as President of Onyx Pharmaceuticals (acquired by Amgen), where he had global strategic oversight and accountability of the business from early product development to commercialization of the Onyx portfolio. Pablo joined Onyx in March 2013, as Executive Vice President, Global Research and Development and Technical Operations, and was named President in October 2013, when Onyx became an Amgen subsidiary. Previously, he was Senior Vice President and Global Head of Clinical Development at Novartis Oncology. From 2007 to 2009, Pablo was Senior Vice President and Chief Medical Officer at Allos Therapeutics (acquired by Spectrum Pharmaceuticals) and, prior to that, Chief Medical Officer of OSI Pharmaceuticals (acquired by Astellas).
Earlier in his career, he served as Assistant Professor of Medicine, University of Colorado Bone Marrow Transplant Program, where he cared for patients undergoing stem cell transplants. Pablo earned his medical degree from University of Buenos Aires School of Medicine, and he completed his fellowship in Hematology and Oncology at the Mount Sinai Medical Center, New York and a fellowship in Stem Cell Transplantation at the University of Colorado Health Sciences Center.
He is a member of the Board of Directors for Fusion Pharmaceuticals, Repertoire Immune Medicines and Synthekine. He serves on the Board of Trustees for the Bay Area Discovery Museum and is a member of the Council on Foreign Relations. He previously served as a board member for CRISPR Therapeutics, Harpoon Therapeutics, Tizona Therapeutics and Tango Therapeutics and was Executive Chairman of Blade Therapeutics.
Dannielle Appelhans joined Rubius as Chief Operating Officer in August of 2021, bringing experience in gene therapy, strategy, manufacturing, supply chain and operations. As COO, she oversees corporate strategy and technical operations for Rubius.
Dannielle joined from Novartis Gene Therapies, where she served as Senior Vice President of Technical Operations and Chief Technical Officer, and oversaw late-stage development, clinical and commercial manufacturing, supply chain and all supporting operational functions for the gene therapy unit and AAV portfolio. Before that role, she served as Senior Vice President, Global Head of Supply Chain Management for Novartis and was responsible for end-to-end supply chain of all Novartis divisions worldwide, across 60-plus plants in more than 120 countries to ensure $50 billion in sales. Since 2014, Dannielle held positions of increasing responsibility in global supply chain, strategy and operational excellence across several divisions within Novartis. Before joining Novartis, Dannielle was a senior engagement manager at McKinsey & Company, working in the pharmaceutical operations practice. Earlier in her career she held roles of increasing responsibility at Eli Lilly and Company.
Dannielle has an MBA from MIT Sloan School of Management, a Master of Science from Massachusetts Institute of Technology and a Bachelor of Science from the University of Michigan in mechanical engineering.
Pepe joined Rubius Therapeutics as Chief Financial Officer in September 2020. Pepe previously served as the Chief Financial Officer of Radius Health, a biopharmaceutical company developing and commercializing endocrine therapeutics. At Radius Health, he was responsible for all financial aspects of the business as well as investor relations, business development and other operational functions. Under Pepe’s leadership, Radius Health was transformed from a clinical-stage company to a fully commercial organization. Pepe was instrumental in financing the company’s commercialization and pipeline investments, executing several business development transactions and building the finance organization, processes and systems. Prior to joining Radius, Pepe was Chief Financial Officer of Innocoll Holdings PLC, acquired by Gurnet Point L.P. Previously, Pepe held numerous financial management positions with increasing responsibilities at Novartis AG, in various divisions, as chief financial officer in Europe, North America, Latin America and held other senior global financial roles.
Pepe received his B.S. in Industrial Civil Engineering from Universidad Tecnica Federico Santa Maria in Valparaiso, Chile, and his M.B.A. from Columbia Business School in New York City.
Christina Coughlin joined Rubius Therapeutics as Chief Medical Officer in January 2020. She brings extensive experience leading clinical development and translational medicine teams and has a track record of building successful drug development organizations, with a particular focus in cellular therapy and oncology
A trained oncologist and immunologist, Dr. Coughlin joins Rubius from Tmunity Therapeutics, Inc., where she served as chief medical officer and was responsible for the development of Tmunity’s CAR-T and TCR-T cellular therapy pipeline across preclinical, regulatory and clinical development activities. Prior to Tmunity, Ltd., Dr. Coughlin served as chief medical officer at Immunocore, where she led the development of the preclinical and clinical pipeline of soluble T cell receptor product candidates recognizing multiple tumor targets, including advancing the lead program from Phase 1 to dual pivotal clinical trials. Earlier, she held positions at several pharmaceutical companies, including executive director of oncology clinical development at Novartis; international project team leader, early development at Morphotek, Inc.; and was an asset team leader in early clinical development at Pfizer’s Oncology Business Unit.
Before entering the pharmaceutical industry, Dr. Coughlin was an instructor in pediatrics at the University of Pennsylvania School of Medicine; completed her postdoctoral research fellowship in the Translational Research Group of the Abramson Family Cancer Research Institute under the direction of CAR-T cell therapy pioneer Carl June, M.D.; and was an attending physician and instructor in the Department of Pediatrics and Division of Oncology at The Children’s Hospital of Philadelphia. She holds an M.D. and Ph.D. from the University of Pennsylvania School of Medicine and a B.S. in mathematics and biology from Temple University.
Spencer Fisk is the Chief Technical Operations Officer of Rubius and brings more than 25 years of experience in Manufacturing and CMC product development. Prior to joining Rubius, Spencer served as VP & Global Head of Cell & Gene Technical Development and Manufacturing at Novartis where he led the CMC development and manufacturing organization to deliver the CAR-T portfolio. Under his leadership, the team successfully registered and launched the first CAR-T cellular therapy product, Kymriah, which has demonstrated transformative efficacy in patients with acute lymphoblastic leukemia. While at Novartis, Spencer also led the process development teams in support of the commercialization of Cosentyx® and the registration and approval of ErelziTM and Rixathon®. Prior to Novartis, he led manufacturing and CMC functions in support of Somavert®, Elonva®, Retavase® and Puregon® while at Merck, formerly Schering Plough, Organon and Covance. Prior to Merck, Spencer held various process development and manufacturing roles at Genentech, Genencor and Novo Nordisk.
Bryan Gillis joined Rubius in August 2018 as the Site Head of our manufacturing facility in Smithfield, RI, and in August of 2019 was named Vice President of Manufacturing. He brings more than 22 years of experience in roles within biotechnology across Process Development, Industrial Affairs, Quality and Manufacturing. Prior to joining Rubius, Bryan held numerous roles of increasing responsibility at Amgen, Lonza, Sanofi and Alexion, where he served as Executive Director of Manufacturing. He has significant experience with the start-up and maturation of manufacturing facilities and organizations.
Bryan holds an MBA from Boston University and B.S. in Biology from Eastern Nazarene College.
Mark Hernon joined Rubius as Chief Information Officer in September of 2021, bringing nearly 35 years of experience in information technology and strategic leadership, including 20 years leading high-performing IT functions at biotech and pharma companies. As CIO, he oversees enterprise IT strategy and operations for Rubius.
Mark joined from digIT strategy, LLC, where he served as Principal and consulted to CIOs, management teams, boards and investors on enterprise digital and IT strategy. Before that, Mark was Senior Vice President and Chief Information Officer at Biogen, where he led the successful revamp of its IT organization across 460 employees. Before joining Biogen, Mark spent nine years with Takeda Pharmaceuticals in roles including Regional CIO for the Americas and Global Head of R&D, QA and HR Systems, and Global Head of R&D Site Strategy and Operations, where he led the global transformation of Takeda’s R&D footprint. Prior to his role with Takeda, Mark spent seven years with Millennium Pharmaceuticals as CIO and VP Operations, leading strategic initiatives to streamline the organization, align with the business, and ultimately manage the group’s transition through the acquisition of Millennium by Takeda.
Mark holds a BS and MS in Industrial and Management Engineering from Rensselaer Polytechnic Institute, and an MBA from the Lally School of Management at Rensselaer Polytechnic Institute.
James “Jim” Jogerst joined Rubius as Chief Business Officer in August of 2021, bringing more than 20 years of experience in developing, structuring and closing high-level deals, including mergers and acquisitions, business development and licensing transactions. As CBO, he leads business development strategy and execution, including strategic partnerships, collaborations and alliances that align with Rubius’ overall corporate strategy.
Jim joins Rubius most recently from Janssen Pharmaceuticals, where he led licensing transactions in the company’s Infectious Diseases and Vaccines business. Before that, Jim spent nearly ten years at Alcon, Inc., where he developed and executed business development and licensing and mergers and acquisitions strategy for Alcon’s three global franchises: surgical, pharmaceutical and vision care. Earlier in his career Jim held executive positions in several investment banking boutiques in Dallas after starting his career in consulting with Arthur Andersen.
Jim has an MBA in Finance and International Business from Pepperdine University and a BA in Economics and Political Science from the University of North Texas. He also holds the Chartered Financial Analyst (“CFA”) designation.
Maiken Keson-Brookes joined Rubius as Chief Legal Officer and Corporate Secretary in November 2019, bringing more than 20 years of international legal experience and working biopharmaceutical companies from the discovery phase all the way through commercialization. She oversees Rubius’ legal and securities matters and intellectual property. Maiken joined Rubius from Synlogic, Inc., where she served as general counsel. Prior to Synlogic, she served as senior vice president and general counsel at uniQure, a gene therapy company. Before uniQure, she was senior vice president and general counsel at Forum Pharmaceuticals, where she established the company’s first legal department and built a legal team to support all aspects of the business. Earlier, Maiken held legal roles at Genzyme and Biogen. While with Biogen, she served as attorney for the ex-U.S. launch of several products and provided legal oversight for the company’s manufacturing group, including a large-scale manufacturing facility construction project.
Maiken holds master of laws and bachelor of laws degrees from Kings College University of London.
Rashmi Kshirsagar joined Rubius as Vice President, Technical Development in October 2019 and is responsible for leading the teams within Technical Operations that focus on process, product and analytical innovation to advance the RED PLATFORM®. She also oversees Chemistry, Manufacturing and Controls (CMC) development for Rubius’ Red Cell Therapeutic™ product candidates that transition from the discovery phase through clinical development.
Rashmi brings to Rubius more than 20 years of experience in Manufacturing and CMC Product Development. Prior to her role at Rubius, Rashmi spent 16 years at Biogen, most recently serving as Senior Director of Protein Development in Pharmaceutical Operations & Technology, where she was responsible for developing and supporting preclinical to post-commercialization manufacturing processes for internal and partnered biopharmaceutical programs. She has experience in CMC project management, led cell culture process development activities for biologics, influenced scientific endeavors for fundamental process understanding and led cross-functional teams in technical development. Rashmi began her career at Millennium Pharmaceuticals in Process Development Technology.
Rashmi has been active for more than 20 years in the scientific community by presenting at conferences, publishing scientific papers and book chapters as well as planning conferences, conference sessions and workshops, and participating in industrial forums and consortia. She holds a Bachelor of Chemical Engineering from the University Department of Chemical Technology, University of Bombay, Mumbai, India, and a Ph.D. from the University of Minnesota.
Jeffrey Lee joined Rubius Therapeutics in September 2021 as Head of Intellectual Property. He is an accomplished patent attorney with nearly 15 years of experience in counseling clients on a variety of legal issues ranging from patent prosecution, licensing, freedom-to-operate, due diligence, product development, trade secrets, and patent litigation. Jeff joined Rubius from Sanofi, where he served as Senior Patent Counsel and was responsible for numerous clinical stage assets, primarily focused in the oncology and immunology/inflammation therapeutic areas. Prior to Sanofi, Jeff was an intellectual property litigation associate in the New York offices of Steptoe & Johnson LLP and Mayer Brown LLP, where he worked on several high-profile litigations involving antibody technology. Jeff started his legal career as an intellectual property attorney in the New York office of WilmerHale LLP.
Jeff earned his B.A. in Biochemistry and Classical Studies from the University of Pennsylvania, his Ph.D. in Neurobiology and Anatomy from the University of Utah, and his J.D. from American University Washington College of Law. He is licensed to practice law in New York, New Jersey, and Massachusetts, and is a registered patent attorney with the United States Patent and Trademark Office.
Lori Murray joined Rubius in 2018, and serves as the Chief Corporate Affairs Officer, leading internal and external communications, patient advocacy and corporate social responsibility. Prior to her role at Rubius, she was the Head of Corporate Affairs at Onyx Pharmaceuticals (acquired by Amgen), where she served on the leadership team and oversaw internal and external communications, global patient advocacy and provided investor relations support to Amgen for Onyx Pharmaceuticals.
Earlier in her career, she held corporate, product and marketing communications positions at WeissComm Partners, now W2O Group, a healthcare communications agency, Applied Biosystems, now Thermo Fischer Scientific, and ReGen Biologics, now Stryker. She began her career working on political campaigns in her home state of California.
Lori holds an MBA from the University of San Francisco and a B.A. in Rhetoric and Communications from the University of California, Davis.
Dwight Morrow joined Rubius in 2019, and serves as Vice President of Platform and Innovation, leading innovation across the RED PLATFORM® with a focus on hematopoietic stem and progenitor cells, novel gene delivery and expression technologies, and translation of in vivo erythropoiesis to in vitro Red Cell Therapeutic™ (RCT) production.
Dwight brings 25 years of experience in early target and drug discovery and development, including CMC, IND-enabling studies, GLP tox, pre-IND and IND submission. Prior to his role at Rubius, he was the Vice President of Preclinical Development at Magenta Therapeutics, where he helped build the company from a startup to a clinical stage company and served as project head for its lead hematopoietic stem cell program from inception through IND filing and Phase 1 clinical programs. Before that, Dwight spent 17 years at GlaxoSmithKline in the High Throughput Screening department, and then as Director of Discovery in the Stem Cell and Regenerative Medicine Units before becoming Senior Director of Target Sciences, responsible for the target validation strategy for Metabolic and Cardiovascular therapy areas, including diabetes, kidney diseases, muscle and cardiovascular diseases.
Earlier in his career, Dwight worked in genetics, molecular and cellular biology with a focus on technology development, including novel molecular biological techniques, yeast genetics and chromosome manipulation.
Dwight has been active for more than 30 years in the scientific community by presenting at conferences and publishing scientific papers and book chapters. Additionally, Dwight is listed on seven patents and has received numerous grants and awards throughout his career.
Dwight holds a Ph.D. in Immunology and Genetics from Case Western Reserve University, Institute of Pathology and a B.A. in Biology from Swarthmore College.
Joanne Protano joined Rubius as Vice President of Finance in May 2017 and was promoted in October 2018, to Senior Vice President of Finance & Operations. Joanne brings to Rubius more than 25 years of experience in finance and accounting, including 18 years in senior management roles in publicly traded companies. Prior to joining Rubius, she served as the SVP Finance, New Ventures at Flagship Pioneering where she oversaw the financial and administrative operations of VentureLabs companies and provided guidance on financial planning, cash flow management, capital structure and financings, corporate governance, accounting and finance infrastructure and operations. From 2007 until joining Flagship, Joanne was the Vice President of Finance, Chief Financial Officer and Treasurer of Novelos Therapeutics, Inc. (now Cellectar Biosciences). Prior to Novelos, she held various senior management roles with Ascential Software, Inc. and predecessor companies until Ascential’s acquisition by IBM, including Vice President and Chief Financial Officer of the Ascential Software division of Informix Software and Corporate Controller of Ardent Software. Joanne began her career at Deloitte & Touche LLP where she was an audit manager serving technology and healthcare clients.
Joanne holds a B.S. in business administration from Bryant College.
Theo Proukou joined Rubius as Vice President & Head of Human Resources in August 2017 and was promoted in February 2019 to Chief People Officer. Theo brings to Rubius more than 20 years of experience in the pharma, biotech and tech industries. He spent 16 years at Novartis Pharmaceuticals holding numerous roles with increasing responsibilities in Human Resources, Marketing and Sales. In 2014, Theo joined Vertex Pharmaceuticals leading the HR team for Commercial and G&A. In 2015, he was promoted to Vice President of Talent Acquisition and Development where he led efforts to recruit, retain and develop talent across the organization. In 2016, Theo joined TripAdvisor, where he led the global HR Business Partner organization until joining Rubius.
Theo holds a MBA in Marketing & Management, a M.S. in Education for Counseling & Psychology and a B.A. in Journalism & Mass Communication. All of his degrees are from St. Bonaventure University.
Jessica St. Peter joined Rubius as Vice President of Program Management in July 2019, and in November 2019 was additionally named head of Strategic Operations. In her role, she is responsible for implementing and developing a strong program management function responsible for managing cross functional teams to ensure the alignment and execution of our development programs, including managing program scope, timelines, deliverable, risks, decisions and communications. Jessica brings to Rubius more than 18 years of extensive biotechnology and pharmaceutical industry experience in global drug development. Jessica spent more than a decade at Novartis Oncology, where she held numerous roles of increasing responsibility in clinical development and strategic development operations encompassing the entire oncology pipeline. In 2016, Jessica pursued her entrepreneurial interests and built both a network marketing business in health and wellness and her own consulting business providing start-up biotech companies with clinical development expertise until joining Rubius.
Jessica holds a B.S. in Biology from Western University.
Tamyra Toole joined Rubius in June 2018. She brings to Rubius more than 20 years of regulatory affairs and quality assurance experience in the biotechnology and pharmaceutical industry.
Prior to joining Rubius, she served as an independent regulatory affairs consultant to biotechnology companies. Prior to her role as a consultant, Tamyra was the Vice President of Regulatory Affairs and Quality Assurance at Infinity Pharmaceuticals, where she built the regulatory and quality teams and was responsible for the global regulatory strategy and the company’s compliance with quality regulations and standards. Previously, Tamyra held positions in regulatory affairs and quality assurance at NitroMed, Wyeth Pharmaceuticals, Millennium Pharmaceuticals and Organogenesis, Inc. She has experience in the development of drugs, biologics and early cell therapies across multiple therapeutic areas. Prior to working in drug development, Tamyra held various positions in the Department of Nursing at Brigham and Women’s Hospital.
Tamyra holds a B.S. in nursing from Villanova University and a J.D. from the Catholic University of America.
Laurence Turka, M.D., joined Rubius as Chief Scientific Officer in January 2020. Larry is an internationally recognized, physician-scientist in autoimmunity and translational immunology with a distinguished career working in academia and, more recently, industry.
Larry joined Rubius from Rheos Medicines, where he was a co-founder and served as Chief Scientific Officer. During his time at Rheos, he built its portfolio of novel therapies targeting the metabolism of immune cells, made key leadership hires, and was instrumental in securing a strategic collaboration between Rheos and Roche. Prior to Rheos, he was an Entrepreneur-in-Residence at Third Rock Ventures, where he played a leading role in the creation of Rheos and provided immunology expertise in evaluating multiple company-building opportunities. Before joining venture capital, Larry spent 30 years working in academia, most recently serving as the Harold and Ellen Danser Professor of Surgery and Professor of Medicine at Harvard Medical School and Massachusetts General Hospital.
Among the notable discoveries of Larry’s laboratory were novel approaches to transplantation tolerance, the role of Toll-like receptors in T cells and pathways required for the maintenance of regulatory T cell function. Larry was also an early leader in the field of T cell costimulation and contributed to the development of abatacept and belatacept for the treatment of rheumatoid arthritis and renal transplantation.
He is a former President of the American Society of Transplantation, Chair of the NIAID Board of Scientific Counselors and Editor in Chief of The Journal of Clinical Investigation. He is currently the Deputy Director of the Immune Tolerance Network, serves on the Scientific Steering Committee of the Parker Institute for Cancer Immunotherapy and is the Harold and Ellen Danser Professor of Surgery (part-time) at Harvard Medical School. He was elected to membership in the American Society for Clinical Investigation in 1995, and the Association of American Physicians in 2003.
Larry received his M.D. from the Yale University School of Medicine, trained in internal medicine at Yale-New Haven Hospital and in nephrology at the Brigham and Women’s Hospital/Harvard Medical School.
Elhan Webb, CFA, joined Rubius in November 2020 and serves as Vice President of Investor Relations. She brings more than 20 years of diverse international experience across investor relations, business development, investment analysis and portfolio management in the healthcare and biotechnology fields.
Prior to Rubius, Elhan was responsible for heading investor relations at Radius Health and Genfit. During her time at Roche, she led IR activities for Roche Diagnostics. She also held business development roles at Roche Molecular Diagnostics and Morphochem.
Earlier in her career, Elhan spent more than a decade in Europe managing and leading investments in the healthcare sector at financial institutions such as BB Biotech-Bellevue Asset Management, Cantrade-UBS and Lombard Odier.
Elhan is a CFA Charterholder and has an MBA from the University of Southern California and a B.A. in Economics from Bogazici University in Istanbul, Turkey.
Greg brings more than 25 years of quality related experience to Rubius. He joins the company from bluebird bio, Inc., where he most recently served as vice president, quality. During the four years he spent at the company, Greg oversaw a 10-fold expansion of the quality unit to support multiple gene therapy clinical trials and to prepare for commercial production in the U.S. and Europe. Under his leadership, he established a culture of quality dedicated to patient safety and data integrity. Prior to bluebird bio, Greg spent 10 years at Dendreon Pharmaceuticals, LLC, most recently serving as director, corporate quality. While there, he established the corporate quality vision and mission and the company’s strategic roadmap for continuous improvement in quality systems. He also led critical initiatives, including regulatory interactions and the successful transition from clinical to commercial production upon product approval. Earlier, Greg was a supervisor of bioanalytic chemistry at BioPort Corporation in Michigan and lead medical technologist in the toxicology testing center at Sparrow Health System in Michigan. Greg received his B.S. in forensic science from Michigan State University.
Ines Verdon joined Rubius as Vice President, Clinical Development in April 2021. She oversees the development, strategy and execution of several clinical development programs at Rubius.
Ines brings more than 20 years of academic and pharmaceutical experience in clinical development in the areas of oncology, infectious disease, cardiovascular disease and molecular diagnostics. She also has experience across drug safety and pharmacovigilance, as well as medical training in cardiothoracic, general surgery, and intensive care.
During her career, Ines has served as the Senior Medical Lead as well as Global Safety Lead on Phase I, II and III clinical trials. Most recently, Ines joined Rubius from Sierra Oncology where she was the Medical Lead in Oncology for Phase III and Phase I/II clinical trials. Before that, Ines was the Medical Director at Onyx, a subsidiary of Amgen, and held positions at Gilead and Epigenomics earlier in her career.
Ines holds an M.D. from Goethe‐University in Frankfurt, Germany and completed a doctoral thesis in the Department of Pharmacology at the University of Bonn, Germany. She also held a postdoctoral research fellowship position in the Department of Surgery at the University of California, San Francisco.